

CITATION REPORT

List of articles citing

The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization

DOI: 10.3390/diagnostics11020339
Diagnostics, 2021, 11, .

Source: <https://exaly.com/paper-pdf/79134999/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
30	Mismatch Repair Status Characterization in Oncologic Pathology: Taking Stock of the Real-World Possibilities. <i>Journal of Molecular Pathology</i> , 2021 , 2, 93-100	0.4	4
29	Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. <i>Cancer Cell International</i> , 2021 , 21, 266	6.4	7
28	Special Issue: Molecular Biomarkers in Solid Tumors. <i>Genes</i> , 2021 , 12,	4.2	0
27	What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy. <i>Journal of Molecular Pathology</i> , 2021 , 2, 147-172	0.4	3
26	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021 ,	2.2	5
25	ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. <i>Future Oncology</i> , 2021 , 17, 4607-4618	3.6	0
24	Intratumor morphologic and transcriptomic heterogeneity in BRAF-mutated metastatic colorectal adenocarcinomas. <i>ESMO Open</i> , 2021 , 6, 100211	6	1
23	Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients. <i>Frontiers in Oncology</i> , 2021 , 11, 735476	5.3	0
22	Update on cytology samples for the use of molecular pathology and other ancillary tests in the move towards next-generation sequencing. <i>Diagnostic Histopathology</i> , 2021 ,	0.7	
21	Tissue Microarray from Cell Block Material (cbTMA) An Additional Shot for Cytology in the Predictive Pathology Era: The PD-L1 Experience. <i>Journal of Molecular Pathology</i> , 2022 , 3, 15-23	0.4	
20	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.. <i>Frontiers in Molecular Biosciences</i> , 2022 , 9, 834651	5.6	7
19	BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 103647	7	0
18	Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. <i>Histology and Histopathology</i> , 2021 , 18376	1.4	1
17	Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC).. <i>Pathologica</i> , 2022 ,	1.9	0
16	FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. <i>Journal of Personalized Medicine</i> , 2022 , 12, 750	3.6	0
15	Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches. <i>Frontiers in Oncology</i> , 12,	5.3	0
14	Biomarker characterization in endometrial cancer in Italy: first survey data analysis. <i>Pathologica</i> , 2022 , 114, 189-198	1.9	1

13	Molecular subtyping of gastroesophageal dysplasia heterogeneity according to TCGA/ACRG classes.	
12	Standard operating procedures for biobank in oncology. 9,	o
11	HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes. 2022 , 12, 1403	o
10	The Third Joint Meeting on Lung Cancer of the FHU OncoAge (University Côte d'Azur, Nice, France) and the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Understanding New Therapeutic Options and Promising Predictive Biomarkers for Lung Cancer Patients. 2022 , 14, 4327	o
9	A dual decoder U-Net-based model for nuclei instance segmentation in hematoxylin and eosin-stained histological images. 9,	o
8	Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2- Breast Cancer. 2022 , 11, 3545	1
7	Molecular Neuropathology versus Histopathology in the Diagnosis of Central Nervous System Tumors: Review Article about Novel Diagnostic and Investigative Technologies. 2022 , 10, 55-72	o
6	Juggling the Various Facets of Modern Anatomic Pathology: A Perspective. 2023 , 4, 28-30	o
5	Full cost of diagnostic pathology for lung carcinoma in Italy: results from four Pathology Units. 1-12	o
4	Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test. 10,	o
3	FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice. 1-12	o
2	Beyond Histology and Stage: The Signatures to Personalize Immunotherapy. 2023 , 1-14	o
1	HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective. jcp-2023-208767	o